Novel antithrombotics such as dabigatran or rivaroxaban are associated, in some instances, with a decreased risk of intraocular hemorrhage compared with traditional anticoagulant therapy, researchers suggest, according to a report in Medscape.
Dr. Brian VanderBeek of the University of Pennsylvania, in Philadelphia, and colleagues retrospectively conducted two separate analyses of intraocular bleeding risk using data from a large U.S. insurance claims database.
Patients prescribed dabigatran or rivaroxaban from January 2010 through September 2015 were compared with those prescribed warfarin. Similarly, patients started on prasugrel were compared with those started on clopidogrel.
People with a previous diagnosis of intraocular hemorrhage were excluded.